RHHBY

Recent Articles

Gilead Stock Will Rise on Sovaldi® Sales

Gilead's breakthrough Hepatitis C drug, Sovaldi®, will drive revenue and profits for the rest of 2014 and into 2015. More 

Roche Proves You Can’t Judge a Book by Its Cover

Roche stock may not be an NYSE or NASDAQ-listed equity, but when you look at the details, RHHBY is plenty investment-worthy. More 

3 Huge Healthcare Trends Can Fatten Your Portfolio

Healthcare concerns in the U.S. are being addressed by companies in the industry. These 3 issues can lead investors to stock opportunities More 

AstraZeneca Probed Over Heart-Drug Trial

British drug maker AstraZeneca says the U.S. Department of Justice is investigating a clinical trial of its Brilinta heart drug. More 

Our Stock Earnings Rundown – HSY KMB DFS SHW LUV TMO AMGN

A big week for earnings and dividend increases includes these 8 stocks in our portfolio. More 

Roche’s Breast Cancer Drug Approval Is Just the Beginning

It might have been dismissed as irrelevant by most investors, but Roche and its Perjeta could reshape the breast cancer drug landscape. More 

2 Major Pharmaceutical Rivals to Share Drug Data

AstraZeneca and Roche will share drug research data with a third company to build a compound library to accelerate drug development and lower costs. More